{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:47:13Z","timestamp":1792273633820,"version":"4.4.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP08\/00140"],"award-info":[{"award-number":["CP08\/00140"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PS09\/01044"],"award-info":[{"award-number":["PS09\/01044"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006751","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.euroneuro.2011.03.001","type":"journal-article","created":{"date-parts":[[2011,5,20]],"date-time":"2011-05-20T23:25:03Z","timestamp":1305933903000},"page":"680-690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["What we know and what we don't know about the treatment of schizoaffective disorder"],"prefix":"10.1016","volume":"21","author":[{"given":"A.","family":"Murru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Pacchiarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.A.","family":"Nivoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Colom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.euroneuro.2011.03.001_bb0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00004714-200202000-00004","article-title":"Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia","volume":"22","author":"Addington","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"APA","year":"2000"},{"issue":"3","key":"10.1016\/j.euroneuro.2011.03.001_bb0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0924-9338(01)00559-4","article-title":"Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiologic, clinical and prognostic differences","volume":"16","author":"Benabarre","year":"2001","journal-title":"Eur. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2011.03.001_bb0020","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/00004714-200010000-00004","article-title":"Efficacy of divalproex therapy for schizoaffective disorder","volume":"20","author":"Bogan","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1\u20132","key":"10.1016\/j.euroneuro.2011.03.001_bb0025","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jad.2009.05.014","article-title":"Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study","volume":"121","author":"Bonn\u00edn","year":"2010","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.euroneuro.2011.03.001_bb0350","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000318812","article-title":"Stability of schizoaffective disorder in correlation with duration of follow-up: retrospective analysis","volume":"43","author":"Brenner","year":"2010","journal-title":"Psychopathology"},{"issue":"12","key":"10.1016\/j.euroneuro.2011.03.001_bb0030","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1176\/ajp.153.12.1625","article-title":"Fluoxetine augmentation of clozapine treatment in patients with schizophrenia","volume":"153","author":"Buchanan","year":"1996","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2011.03.001_bb0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/schbul\/sbn135","article-title":"Comorbidities and schizophrenia","volume":"35","author":"Buckley","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.euroneuro.2011.03.001_bb0040","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4088\/JCP.09m05564yel","article-title":"A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder","volume":"71","author":"Canuso","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2011.03.001_bb0045","first-page":"15","article-title":"Treatment of schizoaffective disorder","volume":"6","author":"Cascade","year":"2000","journal-title":"Psychiatry Edgmont"},{"issue":"6","key":"10.1016\/j.euroneuro.2011.03.001_bb0050","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1399-5618.2007.00506.x","article-title":"A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type","volume":"9","author":"Chengappa","year":"2007","journal-title":"Bipolar Disord."},{"issue":"5","key":"10.1016\/j.euroneuro.2011.03.001_bb0055","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000228838","article-title":"The diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder and unipolar depression: interrater reliability and congruence between DSM-IV and ICD-10","volume":"42","author":"Cheniaux","year":"2009","journal-title":"Psychopathology"},{"issue":"4","key":"10.1016\/j.euroneuro.2011.03.001_bb0060","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archpsyc.60.4.402","article-title":"A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission","volume":"60","author":"Colom","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2011.03.001_bb0065","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000026540","article-title":"Lamotrigine in the treatment of schizoaffective disorder","volume":"38","author":"Erfurth","year":"1998","journal-title":"Neuropsychobiology"},{"issue":"1","key":"10.1016\/j.euroneuro.2011.03.001_bb0070","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1176\/appi.ps.53.1.94","article-title":"Pharmacologic treatment of hospitalized patients with schizoaffective disorder","volume":"53","author":"Flynn","year":"2002","journal-title":"Psychiatr. Serv."},{"issue":"12","key":"10.1016\/j.euroneuro.2011.03.001_bb0075","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/npp.2010.111","article-title":"Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial","volume":"35","author":"Gaebel","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.euroneuro.2011.03.001_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000104703","article-title":"The treatment of psychotic major depression: is there a role for adjunctive psychotherapy?","volume":"76","author":"Gaudiano","year":"2007","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1399-5618.2007.00556.x","article-title":"Diagnostic guidelines for bipolar disorder: a summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force Report","volume":"10","author":"Ghaemi","year":"2008","journal-title":"Bipolar Disord."},{"issue":"1\u20132","key":"10.1016\/j.euroneuro.2011.03.001_bb0090","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jad.2008.12.017","article-title":"The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials","volume":"115","author":"Glick","year":"2009","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.euroneuro.2011.03.001_bb0095","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/JCP.0b013e3181a443d0","article-title":"A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive","volume":"29","author":"Glick","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2011.03.001_bb0100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/jcp.0b013e31815abf34","article-title":"Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials","volume":"27","author":"Goff","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0165-0327(98)00032-9","article-title":"First episode in bipolar disorder: misdiagnosis and psychotic symptoms","volume":"50","author":"Gonz\u00e1lez-Pinto","year":"1998","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.euroneuro.2011.03.001_bb0110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4088\/JCP.v62n0112e","article-title":"Pharmacologic treatment of patients hospitalized with the diagnosis of schizoaffective disorder","volume":"62","author":"Grieger","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.euroneuro.2011.03.001_bb0115","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/2047-783X-14-8-367","article-title":"Maintenance electroconvulsive therapy for comorbid pharmacotherapy-refractory obsessive-compulsive and schizoaffective disorder","volume":"14","author":"Hanisch","year":"2009","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0120","first-page":"35","article-title":"Long-term use of valproate in primary psychiatric disorders","volume":"50","author":"Hayes","year":"1989","journal-title":"J. Clin. Psychiatry"},{"issue":"33","key":"10.1016\/j.euroneuro.2011.03.001_bb0125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1192\/S0007125000297730","article-title":"Cognitively-oriented psychotherapy for early psychosis (COPE). Preliminary results","volume":"172","author":"Jackson","year":"1998","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1348\/014466501163481","article-title":"Cognitively oriented psychotherapy for early psychosis (COPE): a 1-year follow-up","volume":"40","author":"Jackson","year":"2001","journal-title":"Br. J. Clin. Psychol."},{"issue":"9","key":"10.1016\/j.euroneuro.2011.03.001_bb0135","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1017\/S0033291705004927","article-title":"A controlled trial of cognitively oriented psychotherapy for early psychosis (COPE) with four-year follow-up readmission data","volume":"35","author":"Jackson","year":"2005","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.euroneuro.2011.03.001_bb0140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0447.2009.01424.x","article-title":"Treatment of schizoaffective disorder \u2014 a challenge for evidence-based psychiatry","volume":"121","author":"J\u00e4ger","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0145","article-title":"Schizoaffective disorder-an ongoing challenge for psychiatric nosology","volume":"18","author":"J\u00e4ger","year":"2010","journal-title":"Eur. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2011.03.001_bb0150","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00004714-200108000-00002","article-title":"A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder","volume":"21","author":"Janicak","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0155","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2011.03.001_bb0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004714-200102000-00007","article-title":"Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies","volume":"21","author":"Keck","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.euroneuro.2011.03.001_bb0165","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1176\/ps.46.12.1254","article-title":"Heavy utilization of inpatient and outpatient services in a public mental health service","volume":"46","author":"Kent","year":"1995","journal-title":"Psychiatr. Serv."},{"issue":"2","key":"10.1016\/j.euroneuro.2011.03.001_bb0170","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4088\/JCP.v63n0210","article-title":"Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature","volume":"63","author":"Ketter","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2011.03.001_bb0175","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/YCO.0b013e3281a305ab","article-title":"Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease\u2014there is no schizoaffective disorder","volume":"20","author":"Lake","year":"2007","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0180","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jad.2004.05.008","article-title":"Efficacy and safety of long-acting risperidon in stable patients with schizoaffective disorders","volume":"83","author":"Lasser","year":"2004","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.euroneuro.2011.03.001_bb0185","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/WNF.0b013e31815cba78","article-title":"Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit","volume":"31","author":"Lerma-Carrillo","year":"2008","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2011.03.001_bb0190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4088\/JCP.v65n0206","article-title":"Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Leucht","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2011.03.001_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003834.pub2","article-title":"Lithium for schizophrenia","author":"Leucht","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"10.1016\/j.euroneuro.2011.03.001_bb0200","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1176\/ajp.156.8.1138","article-title":"Treatment of schizoaffective disorder and schizophrenia with mood symptoms","volume":"156","author":"Levinson","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2011.03.001_bb0205","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.psychres.2008.10.012","article-title":"Maintenance electroconvulsive therapy: an alternative treatment for refractory schizophrenia and schizoaffective disorders","volume":"175","author":"L\u00e9vy-Rueff","year":"2010","journal-title":"Psychiatry Res."},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2011.03.001_bb0210","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.schres.2007.07.022","article-title":"Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis","volume":"96","author":"Lincoln","year":"2007","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2011.03.001_bb0220","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000284825","article-title":"Factors influencing the long-term outcome of schizoaffective disorders","volume":"26","author":"Marneros","year":"1993","journal-title":"Psychopathology"},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2011.03.001_bb0225","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jad.2007.08.009","article-title":"The longitudinal polymorphism of bipolar I disorders and its theoretical implications","volume":"107","author":"Marneros","year":"2008","journal-title":"J. Affect. Disord."},{"issue":"7","key":"10.1016\/j.euroneuro.2011.03.001_bb0230","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.4088\/JCP.08m04408","article-title":"Treatment nonadherence and neurocognitive impairment in bipolar disorder","volume":"70","author":"Martinez-Aran","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2011.03.001_bb0235","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1600-0047.2004.00295.x","article-title":"Novel antipsychotics in bipolar and schizoaffective mania","volume":"109","author":"Mensink","year":"2004","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0240","first-page":"16","article-title":"Sodium valproate: its use in primary psychiatric disorders","volume":"7","author":"McElroy","year":"1987","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0245","series-title":"Treatment non-adherence amongst schizoaffective bipolar patients: an unsolved question","author":"Murru","year":"2010"},{"issue":"2","key":"10.1016\/j.euroneuro.2011.03.001_bb0250","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1176\/ps.2009.60.2.210","article-title":"Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients","volume":"60","author":"Olfson","year":"2009","journal-title":"Psychiatr. Serv."},{"issue":"3","key":"10.1016\/j.euroneuro.2011.03.001_bb0255","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11065-009-9109-y","article-title":"What do we know about neuropsychological aspects of schizophrenia?","volume":"19","author":"Palmer","year":"2009","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0260","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.euroneuro.2011.03.001_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/j.1440-1614.2005.01516.x","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders","volume":"39","author":"Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders","year":"2005","journal-title":"Aust. NZ J. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2011.03.001_bb0270","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1600-0447.1996.tb09844.x","article-title":"Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study","volume":"94","author":"Salokangas","year":"1996","journal-title":"Acta Psychiatr. Scand."},{"issue":"4","key":"10.1016\/j.euroneuro.2011.03.001_bb0275","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4088\/JCP.08m04227","article-title":"McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients","volume":"70","author":"Salvatore","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0280","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1176\/appi.ajp.157.9.1379","article-title":"Depression in schizophrenia: perspective in the area of \u201cAtypical\u201d antipsychotic agents","volume":"157","author":"Siris","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0285","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.clinthera.2010.01.021","article-title":"Aripiprazole in schizophrenia and schizoaffective disorder: A review","volume":"32","author":"Stip","year":"2010","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.euroneuro.2011.03.001_bb0290","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/2047-783X-15-2-70","article-title":"Cognitive impairment in patients with a schizoaffective disorder: a comparison with bipolar patients in euthymia","volume":"15","author":"Studentkowski","year":"2010","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0295","article-title":"Schizoaffective defective","author":"Swartz","year":"2002","journal-title":"Psychiatr. Times"},{"issue":"1","key":"10.1016\/j.euroneuro.2011.03.001_bb0300","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000054861","article-title":"Maintenance electroconvulsive therapy in affective and schizoaffective disorder","volume":"43","author":"Swoboda","year":"2001","journal-title":"Neuropsychobiology"},{"issue":"6","key":"10.1016\/j.euroneuro.2011.03.001_bb0310","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1600-0447.2007.01072.x","article-title":"Cognitive impairment in schizoaffective disorder: a comparison with non-psychotic bipolar and healthy subjects","volume":"116","author":"Torrent","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0315","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1192\/bjp.174.1.15","article-title":"Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy","volume":"174","author":"Tran","year":"1999","journal-title":"Br. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.euroneuro.2011.03.001_bb0320","doi-asserted-by":"crossref","first-page":"623","DOI":"10.4088\/JCP.v62n0809","article-title":"Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD)","volume":"62","author":"Vieta","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2011.03.001_bb0325","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/schbul\/sbm057","article-title":"Deconstructing bipolar disorder: a critical review of its diagnostic validity and a proposal for DSM-V and ICD-11","volume":"33","author":"Vieta","year":"2007","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.euroneuro.2011.03.001_bb0330","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/15622970701530917","article-title":"A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone","volume":"9","author":"Vieta","year":"2008","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.03.001_bb0335","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1600-0447.2005.00744.x","article-title":"Schizoaffective disorder \u2014the reliability of its clinical diagnostic use","volume":"113","author":"Vollmer-Larsen","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"issue":"4","key":"10.1016\/j.euroneuro.2011.03.001_bb0340","doi-asserted-by":"crossref","first-page":"562","DOI":"10.4088\/JCP.08m04261","article-title":"Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial","volume":"70","author":"Zisook","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.euroneuro.2011.03.001_bb0345","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4088\/JCP.09m05699gre","article-title":"Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial","volume":"71","author":"Zisook","year":"2010","journal-title":"J. Clin. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X1100040X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X1100040X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:50:02Z","timestamp":1760377802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X1100040X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0924977X1100040X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2011.03.001","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What we know and what we don't know about the treatment of schizoaffective disorder","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2011.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}